New Market Research Report: Targeted Therapies In Asthma: KOL Insight

Competition heating up as developers struggle to differentiate pipeline asthma antibodies

Innovative monoclonal antibodies are breathing new life into the treatment of severe asthma. But with many of them targeting similar populations and providing similar benefits, finding a competitive edge won't be easy.

Learn how key opinion leaders (KOLs) expect developers to differentiate their pipeline asthma antibodies in KOL Insight: Targeted Therapies in Asthma.

You'll hear how 12 US and European KOLs think the competitive landscape will evolve as pipeline drugs challenge mainstay treatment, Xolair, and GlaxoSmithKline's Nucala-the first new antibody to market.

Full Report Details at
- http://www.fastmr.com/prod/1152004_targeted_therapies_asthma_kol.aspx?afid=301

View: North American KOLs, EU KOLs, marketed antibodies, pipeline antibodies

Plus: Order the report and you'll also receive three quarterly FirstWord Therapy Trends Update Bulletins absolutely free!

Answering Key Questions

Get answers to key questions about marketed and pipeline monoclonal antibodies for severe asthma:

Marketed Drugs

Anti-IgE Antibodies:

* Xolair (omalizumab; Novartis/Roche) - Is Xolair's market share at risk from new or pipeline antibody treatments?

Anti-IL-5 Antibodies:

* Nucala (mepolizumab; GlaxoSmithKline) - Is Nucala's first to market advantage enough to protect it against competitors in the pipeline?

Pipeline Drugs

Anti-IgE Antibodies:

* Ligelizumab (formerly QGE031; Novartis) - If approved, can ligelizumab increase the eligible anti-IgE patient population? By how much?

Anti-IL-5 Antibodies:

* Cinqair (reslizumab; Teva) - Will Cinquair's route of administration keep it from gaining a foothold in the market?
* Benralizumab (formerly MEDI-563; AstraZeneca) - Will the CALIMA and SIROCCO trials reveal which patient population is most likely to benefit from benralizumab?

Anti-IL-13 Antibodies:

* Tralokinumab (AstraZeneca) - Will its biweekly dosing schedule make it harder for tralokinumab to compete with Roche's lebrikizumab?
* Lebrikizumab (Roche) - How do KOLs view the results of the discontinued the LUTE and VERSE trials?

Anti-IL-13/Anti-IL-4 Antibodies:

* Dupilumab (anti-IL-4 receptor alpha antibody; Sanofi/Regeneron) - How do KOLs think dupilumab will fit into the severe asthma treatment paradigm?
* QBX258 (combination anti-IL-4 VAK694, and anti-IL-13 dectrekumab; Novartis) - If approved, how will QBX258 affect market share for anti-IL-13 therapies such as tralokinumab and lebrikizumab?

Top takeaways

* Severe asthma market small but significant: Although a small percentage of the overall asthma market, severe asthma patients are an important population for drug makers. Find out why.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Biosimilars in Oncology: KOL Insight
- Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation
- Rheumatoid Arthritis: KOL Insight
- OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2024
- PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023